within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA04_Dalbavancin;

model Dalbavancin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.388888888888889e-08,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.010199999999999999,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.008199999999999999,
    k12 = 1e-08,
    k21 = 1e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dalbavancin</td></tr><tr><td>ATC code:</td><td>J01XA04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>10.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.05</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity primarily against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and is administered as an intravenous infusion.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are based on data from healthy adult volunteers receiving intravenous dalbavancin. Most studies use a two-compartment model.</p><h4>References</h4><ol><li><p>Carrothers, TJ, et al., &amp; Critchley, I (2020). Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. <i>Clinical pharmacology in drug development</i> 9(1) 21–31. DOI:<a href=\"https://doi.org/10.1002/cpdd.695\">10.1002/cpdd.695</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31087630/\">https://pubmed.ncbi.nlm.nih.gov/31087630</a></p></li><li><p>Turner, NA, et al., &amp; Holland, TL (2022). Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. <i>Trials</i> 23(1) 407–None. DOI:<a href=\"https://doi.org/10.1186/s13063-022-06370-1\">10.1186/s13063-022-06370-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35578360/\">https://pubmed.ncbi.nlm.nih.gov/35578360</a></p></li><li><p>Colaneri, M, et al., &amp; Seminari, E (2024). Optimizing Antibiotic Therapy for Intravenous Drug Users: A Narrative Review Unraveling Pharmacokinetics/Pharmacodynamics Challenges. <i>European journal of drug metabolism and pharmacokinetics</i> 49(2) 123–129. DOI:<a href=\"https://doi.org/10.1007/s13318-024-00882-8\">10.1007/s13318-024-00882-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38332425/\">https://pubmed.ncbi.nlm.nih.gov/38332425</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01XA04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dalbavancin;
